Sonidegib, a Smoothened Inhibitor, Promotes Apoptosis and Suppresses Proliferation of Natural Killer/T-Cell Lymphoma

Shengquan Liu
Chuntuan Li
Pengliang Xin
Yan Zheng
Qunyi Peng
Yahong Xu
Ying Luo
Yishen Wu
Xiongpeng Zhu

Background: Dysregulation of the Hedgehog (Hh) pathway modulates various aspects of hematologic and solid tumors, but its effects in human Natural killer/T-cell lymphoma (NKTCL) are unclear. Moreover, no study has examined the consequences of pharmacologically inhibiting Hh signaling in NKTCL cell lines.

Material/Methods: In this study, the expression of Smoothened (Smo) and Glioma-associated oncogene 1 (Gli1) in NKTCL tissue were scrutinized. Two human NKTCL cell lines, SNK6 and SNT8, were subjected to various doses of sonidegib (a Smo inhibitor) and incubated for distinct durations. The cell apoptosis was examined by flow cytometry, CCK-8 assay was run to assess proliferation, and protein levels were quantified by Western blotting.

Results: Both Smo and Gli1 expression were higher in NKTCL tissue than in Lymphoid Reactive Hyperplasia (LRH). Sonidegib significantly suppressed proliferation in NKTCL cells and the effect was dose-dependent. Further analysis revealed that sonidegib treatment elevated the number of apoptotic cells in a dose- and time-dependent manner. In addition, sonidegib downregulated Smo and Gli1 expression in NKTCL cells.

Conclusions: The Hh pathway is crucial to the development of NKTCL and thus holds huge promise as a treatment for this disease.

MeSH Keywords: Apoptosis • Hedgehogs • Natural Killer T-Cells

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/918812
Background

NKTCL, which is more common in Asian than in Western countries, is an aggressive non-Hodgkin lymphoma type with poor clinical outcomes [1,2]. It is the most frequently diagnosed type of mature T/NK-cell neoplasms in China, and is the second most common subtype, after diffuse large B-cell lymphoma, of all lymphoid neoplasms subtypes [1,3]. There is no standard treatment strategy for NKTCL patients. Because of the overexpression of multidrug-resistant genes, anthracycline-based chemotherapy is poorly effective [4]. Application of radiotherapy has greatly improved the prognosis of early-stage NKTCL [5]. Some studies have reported that NKTCL patients with refractory or relapsed disease benefit from receiving an L-asparaginase-containing regimen [6,7], but at relapse or advanced stage, patients with NKTCL have sub-optimal outcomes. Thus, novel treatments are needed for NKTCL.

The Hh pathway is essential for embryonic development [8]. Statistics indicate that about 25% of all cases of cancer-related mortality show signs of abnormal Hh signaling [9]. Dysregulation of this pathway leads to hematologic malignancies, including acute leukemia [10–12], chronic myeloid leukemia [13], chronic lymphocytic leukemia [14,15], lymphoma [16], and multiple myeloma [17]. Meanwhile, the Hh pathway modulates the functions of leukemia stem cells, which have been reported to be an important cause of chemo-resistance and relapse of cancers [8,18,19]. For this reason, blockade of Hh signaling may prevent hematological malignancies.

The Hh signaling is initiated by binding of 3 Hh ligands: Desert hedgehog (Dhh), Indian hedgehog (Ihh), and Sonic hedgehog (Shh). In its inactive form, the 7-transmembrane protein Smo is inhibited by a 12-transmembrane protein called Patched (Ptc) in the absence of Hh [20]. Binding of Hh ligand to Ptc activates Hh signaling, which relieves Smo inhibition, thereby activating nuclear localization of Gli1. Gli1 then activates tumorigenesis-associated genes (e.g., Bcl-2, Myc, Cyclin-D1, SNAI1, and SOX2) [21]. A number of Hh signaling pathway inhibitors are currently under clinical development, specifically for Smo, the key receptor involved in this pathway. As a result, sonidegib, which is a specific inhibitor of Smo, was approved by the FDA for basal cell carcinoma (BCC) in 2015. The present study explored the dysregulation of the Hh pathway in NKTCL patients and the impact of sonidegib on apoptosis and proliferation of NKTCL cell lines.

Material and Methods

Clinical data and treatment

Clinical characteristics and tumor specimen were harvested from 30 patients—18 males and 12 females—from 2011 to 2018 at the First Hospital of Quanzhou Affiliated to Fujian Medical University. The WHO classification of lymphoid neoplasms was applied for patient selection [22]. The use of specimens was approved by the Regional Ethics Committee of the First hospital of Quanzhou Affiliated to Fujian Medical University.

Determination of Smo and Gli1 expression in human NKTCL tissue by immunohistochemistry (IHC)

Paraffin-embedded specimens were obtained from 30 individuals with newly diagnosed NKTCL and 10 individuals with LRH between 2011 and 2018 at the First Hospital of Quanzhou Affiliated to Fujian Medical University. The sampled were subjected to IHC staining assay utilizing the following polyclonal antibodies: anti-Smo (1: 100) and anti-Gli1 (1: 150) (Abcam, Cambridge, UK). We then counted all tumor cells and Smo or Gli1 staining tumor cells using a microscope (+400) in 4 fields. The percentage score was determined by the average percentage of tumor cells with positive staining: 0 (<10%), 1 (11–20%), 2 (21–50%), 3 (51–75%), and 4 (>76%). The intensity score depended on the staining intensity: 0 (negative), 1 (weak brown), 2 (brown), and 3 (strong brown). The level of Smo or Gli1 expression was obtained by multiplying percentage score and intensity score, divided into 4 groups: negative (−) (0), positive (+) (1–3), positive (+++) (4–7), and positive (++++) (8–12).

Cell culture and cell lines

Human NKTCL cell lines SNK6 and SNT8 (Leeyond Technology Co., Xiamen, China) were cultured in RPMI-1640 (Thermo Fisher Scientific, Inc., Shanghai, China) medium mixed with 200 U/ml IL-2 (Sigma-Aldrich, USA), 100 U/ml penicillin/100 μg/ml streptomycin (HyClone, Utah, USA), and 10% FBS (Cellmax, Beijing, China) in a humidified incubator at 37°C with 5% CO₂. We replaced the cell medium every 2–3 days. NKTCL cells in logarithmic growth phase were used for the following experiments. Human peripheral blood mononuclear cells (PBMC) were isolated from a healthy volunteer.

Proliferation detection with CCK-8

Cells in logarithmic growth phase were grown on 96-well plates (1×10⁴ cells/well). Thereafter, 200 ul sonidegib (Selleck Chemicals, Houston, USA) at concentrations of 0, 5, 10, 20, 30, 40, and 50 μM was added to the wells. Cells of the control group were treated with an equivalent volume of DMSO.
Figure 1. Smo and Gli1 expression in human NKTCL tissue and NKTCL cell lines. (A) Smo expression in NKTCL tissue by IHC. (B) Gli1 expression in NKTCL tissue by IHC. (C) Smo and Gli1 protein expression in PBMC, SNK6 and SNT8 cells.

Table 1. Smo and Gli1 expression in human NKTCL tissue.

|        | Total n | −   | +  | ++ | +++ | Positive (%) | Z    | P     |
|--------|---------|-----|----|----|-----|--------------|------|-------|
| Smo    | NKTCL   | 30  | 10 | 12 | 5   | 3            | 66.7 | −3.396| 0.001 |
|        | LRH     | 10  | 10 | 0  | 0   | 0            |      |       |       |
| Gli1   | NKTCL   | 30  | 8  | 10 | 6   | 6            | 73.3 | −2.755| 0.006 |
|        | LRH     | 10  | 8  | 1  | 1   | 1            |      |       |       |

Table 2. Correlation between Smo and Gli1 expression in human NKTCL tissue.

|        | Gli1       | rs    | P    |
|--------|------------|-------|------|
| Smo    | −          | 7     | 1    | 1    | 1    | 0.618 | 0.0003 |
|        | +          | 8     | 4    |      |      |       |       |
|        | ++         | 1     | 1    | 1    | 2    |       |       |
|        | +++        |       | 3    |      |      |       |       |
in place of sonidegib, and a zero-adjustment group was also set up. We then added 10 μl of CCK solution to the cells after 24 h, 48 h, or 72 h, after which the cells were cultured for 2 h at 37°C. The cell culture plate was placed in a microplate reader to read the absorbance at 450 nm. Cell viability (%) = (Absorbance of cells treated with sonidegib - absorbance of zero adjustment) / (Absorbance of control - Absorbance of zero adjustment) × 100%.

### Apoptosis detection by flow cytometry

Cells were treated with 0, 10, or 30 μM sonidegib for 24 h or 48 h, then collected and washed twice with binding buffer, and we adjusted the concentration to 5×10^5-10^6 cells/ml. Cell apoptosis was assessed using the Annexin V-FITC/PI kit (BD Biosciences, USA). Cells were resuspended in 500 μl binding buffer, mixed with 5 μl Annexin V-FITC, and then we added 5 μl propidium iodide (PI). Cells were subsequently incubated

### Table 3. Smo, Gli1 expression in human NKTCL tissue and their association with clinical parameters.

| Parameters | Gender | Total (n) | Smo | Gli1 | P     | Smo | Gli1 | P     |
|------------|--------|----------|-----|------|-------|-----|------|-------|
|            | Male   | 18       | 6   | 7    | 3     | 2   | 0.911| 5     | 9     | 0.981 |
|            | Female | 12       | 4   | 5    | 2     | 1   | 0.244| 4     | 5     | 0.188 |
| Age        | <60 y  | 18       | 5   | 7    | 3     | 3   | 0.222| 8     | 10    | 0.472 |
|            | ≥60 y  | 12       | 5   | 5    | 2     | 0   | 0.222| 8     | 10    | 0.472 |
| ECOG       | 0–1    | 29       | 9   | 12   | 5     | 3   | 0.222| 8     | 10    | 0.472 |
|            | ≥2     | 1        | 1   | 0    | 0     | 0   | 0    | 0     | 1     | 0     |
| Ann arbor  | I–II   | 26       | 8   | 11   | 4     | 3   | 0.540| 6     | 10    | 0.800 |
|            | III–IV | 4        | 2   | 1    | 1     | 0   | 0.150| 2     | 0     | 1     | 1     |
| B symptoms | No     | 22       | 7   | 7    | 5     | 3   | 0.215| 6     | 7     | 0.846 |
|            | Yes    | 8        | 3   | 5    | 0     | 0   | 0.215| 6     | 7     | 0.846 |
| LDH        | <245 U/L| 25       | 7   | 11   | 4     | 3   | 0.251| 7     | 9     | 0.862 |
|            | >245 U/L| 5        | 3   | 1    | 1     | 0   | 1    | 2     | 1     | 1     |
| EBER       | Negative| 6        | 3   | 2    | 1     | 0   | 0.310| 4     | 2     | 0     | 0     | 0.010 |
|            | Positive| 24       | 7   | 10   | 4     | 3   | 0.310| 4     | 8     | 6     | 6     |
| IPI score  | 0–1    | 22       | 6   | 9    | 4     | 3   | 0.173| 5     | 8     | 4     | 5     | 0.527 |
|            | ≥2     | 8        | 4   | 3    | 1     | 0   | 0.173| 3     | 2     | 2     | 2     | 1     |
| PINK score | 0–1    | 26       | 8   | 11   | 4     | 3   | 0.540| 6     | 10    | 5     | 5     | 0.800 |
|            | ≥2     | 4        | 2   | 1    | 1     | 0   | 0.540| 6     | 10    | 5     | 5     | 0.800 |
at 25°C in the dark for 15 min. Apoptosis detection was performed by flow cytometry (BD Biosciences, USA) within 1 h.

**Western blot analyses**

Cells were treated with 0, 10, 20, or 30 μM sonidegib for 48 h. Thereafter, they were washed with PBS followed by treatment with lysis buffer (pH 7.0) mixed with protease inhibitor. The BCA Protein Assay kit (Beyotime, Jiangsu, China) was used to determine protein concentration in the lysates. Subsequently, the protein samples were separated by SDS-PAGE gel electrophoresis, followed by electrotransfer to PVDF membranes before they were immunoblotted with the antibodies against Smo and Gli. Antibodies against GAPDH (Beyotime, Jiangsu, China) served as the loading control. The PVDF membranes were treated with secondary antibody (anti-rabbit) and we used the enhanced chemiluminescence system to visualize the protein bands.

**Statistical analyses**

The fluorescence intensity of Smo and Gli1 between groups was compared by the non-parametric test with grade data. Intergroup comparisons were carried out by the Mann-Whitney U test. The correlation between Smo and Gli1 expression was performed by Spearman rank correlation. Quantitative data are presented as mean±SD. Differences between groups in terms of proliferation and apoptosis were determined by one-way ANOVA. A P-value <0.05 represented statistical significance. All analyses were performed using SPSS software, version 24.0 (SPSS, Inc., Chicago, IL, USA).

**Results**

**Smo and Gli1 were highly expressed in human NKTCL tissues**

We retrospectively evaluated Smo and Gli1 expression in 30 NKTCL tissues (Figure 1, Table 1). We found positive Smo and Gli1 expression in 66.7% (20/30) and 73.3% (22/30) of NKTCL specimens, respectively, while there were 0% (0/10) Smo expression and 20% (2/10) Gli1 expression in LRH specimens. Positive stainings of Smo were mainly localized in the cell membrane and cytoplasm, while positive stainings of Gli1 were mainly localized in the cytoplasm and nucleus. In addition, Smo expression levels were positively correlated with those of Gli1 (Table 2).
Gli1 expression was correlated with EBER in NKTCL patients

We analyzed the correlation between Smo/Gli1 expression and the clinical characteristics of NKTCL to explore the effect of Smo/Gli1 in NKTCL progression. Table 2 shows that Smo expression was not significantly correlated with clinical characteristics. However, overexpression of Gli1 was significantly associated with EBV-encoded RNA (EBER) (P<0.05, Table 3).

Sonidegib suppressed NKTCL cells proliferation

Figure 2 shows that the cell viability of NKTCL cell lines (SNK6 and SNT8) was decreased as the concentration of sonidegib increased. The suppression of NKTCL cells induced by sonidegib treatment was dose-dependent.

Sonidegib promoted apoptosis in NKTCL cells

Compared with control, the apoptotic cells were markedly elevated following treatment with 10 μM or 30 μM sonidegib.
for 24 h or 48 h (P<0.05, Figure 3). Moreover, the number of apoptotic cells markedly increased following incubation with 30 μM sonidegib for 48 h compared to those incubated for 24 h (P<0.05, Figure 3), and the level of apoptosis at 30 μM sonidegib was higher than that of 10 μM sonidegib for 48 h (P<0.05, Figure 3). Promotion of apoptotic NKTCL cells induced by sonidegib treatment was dose- and time-dependent.

Sonidegib downregulated Smo and Gli1 expression

Hh signaling pathway protein expression after exposure to different concentrations of sonidegib is shown in Figure 4. Smo and Gli1 expression were obviously reduced by sonidegib in NKTCL cells (SNK6 and SNT8). Furthermore, increasing the dose of sonidegib significantly enhanced this effect, indicating the inhibitory effect was influenced by the dose. Our findings show that Hh signaling pathway can be suppressed by sonidegib through downregulation of Smo and Gli1 expression in NKTCL cells.

Discussion

Despite improvements achieved through L-asparaginase-containing regimen, patients with advanced-stage or relapsed NKTCL usually have a poor prognosis. Thus, the development of effective strategies to treat NKTCL is urgently needed. This is the first study showing dysregulation of the Hh signaling pathway in NKTCL. We first measured Smo and Gli1 expression in human NKTCL tissue by IHC. Results showed that both Smo and Gli1 expression were highly expressed in NKTCL tissue. Moreover, results showed a correlation between Smo and Gli1 expression in NKTCL, suggesting dysregulation of Hh signaling in NKTCL might be in a canonical activation manner. In addition, we used sonidegib to inhibit Hh signaling pathway in 2 NKTCL cell lines. Based on the NKTCL cell proliferation tests, results revealed that sonidegib effectively suppressed proliferation and this effect was influenced by the dose. Similarly, analysis of cell apoptosis demonstrated that sonidegib treatment enhanced apoptosis in a dose- and time-dependent manner. Moreover, Smo and Gli1 expression were downregulated by sonidegib. These results suggest the potential therapeutic effect on NKTCL by targeting the Hh signaling pathway.

Several studies have reported abnormal Hh signaling in various hematologic malignancies. Liang et al. [10] found that the Hh signaling pathway was upregulated in refractory/relapse acute myeloid leukemia patients. In a T-cell acute lymphoblastic leukemia study reported by Dagklis et al., activation of the Hh pathway was found in 20% of samples [11,12]. In a chronic myeloid leukemia study, the kinetics of Hh signaling activity during the individual medical history correlated with BCR-ABL1 mRNA level and with upcoming molecular relapse [13]. Additionally, Dagklis et al. [11] also showed that short interfering RNA-mediated knockdown or drug inhibition of Gli1 or Smo in T-ALL cell lines reduced cell proliferation. Furthermore, other scholars have reported that the Hh pathway is critical for maintaining of leukemia stem cells [18]. Inhibition of the Hh pathway reduces proliferation and renewal of stem cells, thus providing a potential mechanism for eliminating leukemia stem cells [19].

Recent years have witnessed an increase in studies aimed at developing drugs targeting the Hh signaling pathway, especially Smo, a G-protein-coupled receptor-like molecule which modulates Hh signaling. A number of Smo blockers have been studied in various types of cancers. Sonidegib and Vismodegib were approved by the US FDA for basal cell carcinoma [23,24], while glasdegib was approved for use in combination with low-dose cytarabine to treat acute myeloid leukemia [25]. Most Smo inhibitors bind to and inhibit Smo [21]. It was also reported that sonidegib inhibited cell viability and apoptosis in vivo and in vitro [17,26]. Elsewhere, in a murine model of chronic myeloid leukemia, treatment with sonidegib promoted
the survival and decreased the progression of leukemia in secondary transplants [27]. Moreover, Smo deletion suppressed the number of leukemic stem cells [18].

The results discussed above imply that inhibiting the Hh pathway may be an attractive approach for treating hematologic malignancies. In addition to direct Smo inhibitors, studies are underway to design other inhibitors of the Hh pathway (e.g., Shh monoclonal antibody and Gli inhibitors GANT-61) [21].

The present study has revealed dysregulated Hh signaling in NKTCL, and its important role in NKTCL cell proliferation and tumorigenesis. Inhibiting the Hh signaling with sonidegib suppresses proliferation and promotes apoptosis in NKTCL, indicating it is a promising treatment for NKTCL. However, we did not directly silence Smo, which is a limitation of this study.

Therefore, further detailed studies are needed to increase the clinical utility of current Hh inhibitors in NKTCL.

Conclusions

Smo and Gli1 are key players in the development of NKTCL. Sonidegib was shown to promote apoptosis and suppress NKTCL cell proliferation by downregulating Smo and Gli1 expression. Therefore, blockade of the Hh signaling by sonidegib could be an effective treatment for NKTCL.

Conflicts of interest

None.

References:

1. Au WY, Weisenburger DD, Intragumtornchai T et al: Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood, 2009; 113: 3931–37
2. Tse E, Kwong YL: The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol, 2017; 10: 85
3. Sun J, Yang Q, Lu Z et al: Distribution of lymphoid neoplasms in China. Am J Clin Pathol, 2012; 138: 429–34
4. Wang B, Li XQ, Ma X et al: Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol, 2008; 83: 795–99
5. Bi X, Li Y, Fang H et al: High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer’s ring: Dosimetric analysis and clinical outcome. Int J Radiat Oncol Biol Phys, 2013; 87: 1086–93
6. Jaccard A, Gachard N, Marin B et al: Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood, 2011; 117: 3846–59
7. Yong W, Zheng W, Zhu J et al: L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol, 2009; 88: 647–52
8. Irving DA, Copland M: Targeting hedgehog in hematologic malignancy. Blood, 2012; 119: 2196–204
9. Chahal KK, Parle M, Abagyan R: Hedgehog pathway and smoothened in chronic myeloid leukaemia. Sci Rep, 2016; 6: 25476
10. Liang H, Zheng QL, Fang P et al: Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells. Sci Rep, 2017; 7: 40361
11. Dagklis A, Pauwels D, Lahortiga I et al: Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia. Haematologica, 2015; 100: e102–5
12. Dagklis A, Demeyer S, De Bie J et al: Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and Gli1 inhibitors. Blood, 2016; 128: 2642–54
13. Cea M, Cagnetta A, Cirmena G et al: Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. Leuk Lymphoma, 2013; 54: 342–52
14. Desch P, Asslaber D, Kern D et al: Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene, 2010; 29: 4885–95
15. Hegde GV, Peterson KJ, Emanuel K et al: Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: A potential new therapeutic target. Mol Cancer Res, 2008; 6: 1928–36
16. Kim JE, Singh RR, Che-Vega JH et al: Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol, 2009; 22: 1312–20
17. Blotta S, Jakubikova J, Calimeri T et al: Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood, 2012; 120: 5002–13
18. Zhao C, Chen A, Jamieson CH et al: Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature, 2009; 458: 776–79
19. Diersk C, Beigi R, Guo GR et al: Expansion of Bcr-AbI-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell, 2008; 14: 238–49
20. Scales SI, de Sauvage FJ: Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci, 2009; 30: 303–12
21. Rimkus TK, Carpenter RL, Qasem S et al: Targeting the sonic Hedgehog signaling pathway: Review of smoothened and Gli inhibitors. Cancers (Basel), 2016; 8: 22
22. Swerdlow SH, Campo E, Pileri SA et al: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016; 127: 2375–90
23. Sandhiya S, Melvin G, Kumar SS et al: The dawn of hedgehog inhibitors: Vismodegib, J Pharmacol Pharmacother, 2013; 4: 4–7
24. Burgess CB: Sonidegib: First global approval. Drugs, 2015; 75: 1559–66
25. Hoy SM: Glasdegib: First global approval. Drugs, 2019; 79: 207–13
26. Tse E, Kwong YL: The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol, 2015; 8: 114
27. Irving DA, Zhang B, Kinstrie R et al: Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci Rep, 2016; 6: 25476